Intracavernosal Self-Injection Therapy for the Patients with Erectile Dysfunction: Comparison of Erectile Response and Complications between Bimix and Trimix Solution.
- Author:
Kyung Keun SEO
1
;
Kee Keun SONG
;
Sae Chul KIM
Author Information
1. Chung Ang University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
trimix solution;
erectile response;
complications
- MeSH:
Drug Therapy;
Erectile Dysfunction*;
Fibrosis;
Humans;
Incidence;
Male;
Papaverine;
Phentolamine
- From:Korean Journal of Urology
1997;38(3):306-311
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the efficacy of Bimix solution (27.3 mg/ml papaverine and 0.9 mg/ml phentolamine) versus Trimix solution (18.8 mg/ml papaverine, 0.6 mg/ml phentolamine and 6.3ug/ml prostaglandin El) in terms of erectile response and complications. MATERIALS AND METHODS: We comparatively analyzed the erectile response and the incidence of pain, prolonged erection (>4 hours), and corporal fibrosis of either medication in the 155 impotent patients who used Bimix solution for intracavernous pharmacotherapy (mean duration: 15 months) and thereafter used Trimix solution (mean 12 months). RESULTS: Erectile response to Trimix solution was significantly better than Bimix solution (p<0.01). The mean dose of Bimix solution was higher than Trimix solution (0.43 ml. vs. 0.34 ml, p<0.05). The severe pain enough for impediment to ntercourse occurred in 6.5% of the Trimix group, while no patient of the Bimix group experienced (p<0.01). The corporal fibrosis was noted in 8.4% of the Trimix group and 16.1% of the Bimix group. However, there was no significant difference between the two groups (p=0.08). The incidence of prolonged erection was significantly lower (p<0.05) in the Trimix group (2.6%) than in the Bimix group (12.3%). A total of 139 patients (89.7%) finally selected Trimix solution. CONCLUSIONS: The Trimix solution was more effective and safer than Bimix solution for the treatment of erectile dysfunction.
